<SEC-DOCUMENT>0001737287-22-000012.txt : 20220223
<SEC-HEADER>0001737287-22-000012.hdr.sgml : 20220223
<ACCEPTANCE-DATETIME>20220223160819
ACCESSION NUMBER:		0001737287-22-000012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220223
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220223
DATE AS OF CHANGE:		20220223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		22663584

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>allo-20220223.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2cb99d07-dd52-4e65-8d05-0da2093a6454,g:2b8cea13-1c6b-4c4b-bacc-6d5e7e0851da,d:d19c3483176340bcbb69140b53a9dc2e--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20220223</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV80L2ZyYWc6MjAzZjdmYjUxYTE2NGVjMGJmMzZhYzc3NDllZDlhMTgvdGFibGU6NDIyYjViZmQ2Yjc5NGE0MWFhODM4NDZhNjk4NjFkMzYvdGFibGVyYW5nZTo0MjJiNWJmZDZiNzk0YTQxYWE4Mzg0NmE2OTg2MWQzNl8xLTEtMS0xLTA_29e4d5cb-e2d5-4637-8eb9-ef3ca2824f70">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV80L2ZyYWc6MjAzZjdmYjUxYTE2NGVjMGJmMzZhYzc3NDllZDlhMTgvdGFibGU6NDIyYjViZmQ2Yjc5NGE0MWFhODM4NDZhNjk4NjFkMzYvdGFibGVyYW5nZTo0MjJiNWJmZDZiNzk0YTQxYWE4Mzg0NmE2OTg2MWQzNl8yLTEtMS0xLTA_519950c1-4425-40a7-b649-c8aadcdfb303">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="allo-20220223.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id19c3483176340bcbb69140b53a9dc2e_1"></div><div style="min-height:33.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8xMDY_4cd8f04e-59c0-4688-ba94-634a5826f1e8">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8yNjY_3cf7a794-f36d-4502-b580-830dbddf37ce">February 23, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_______________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8yOTM_38a87e8d-d662-4775-b335-f3c4522aef5e">Allogene Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6MDk1NTQwNDg5NTYzNDExNGEyMDc5NTYyOTY2NzA4NzUvdGFibGVyYW5nZTowOTU1NDA0ODk1NjM0MTE0YTIwNzk1NjI5NjY3MDg3NV8wLTAtMS0xLTA_f63b5e90-0c46-4882-9d24-141375a4f9b8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6MDk1NTQwNDg5NTYzNDExNGEyMDc5NTYyOTY2NzA4NzUvdGFibGVyYW5nZTowOTU1NDA0ODk1NjM0MTE0YTIwNzk1NjI5NjY3MDg3NV8wLTEtMS0xLTA_b386ce20-0cf6-415f-8898-19914dab199d">001-38693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6MDk1NTQwNDg5NTYzNDExNGEyMDc5NTYyOTY2NzA4NzUvdGFibGVyYW5nZTowOTU1NDA0ODk1NjM0MTE0YTIwNzk1NjI5NjY3MDg3NV8wLTItMS0xLTA_32b45fca-d0e1-429c-86fd-01608932d206">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="9" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8zODI_8e1692bc-e01a-4763-b1a3-47586499b1e1">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8zODY_a3abd840-c04d-46ab-bbcf-a33932fb6a8c">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8zOTA_3723d742-3194-4c89-b83a-943025d12305">California</ix:nonNumeric> <ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8zOTM_c4d6cbda-b5e5-46ad-b9c9-88e1c037e292">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV81MDk_edde7a9d-0a06-4b54-b9c4-bf985579368e">650</ix:nonNumeric>) <ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV81MTM_7ff9b300-96d2-4479-bc2d-1786ed857c66">457-2700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6YWY3ZTIzNmQwM2U5NGRhNzkwM2NlYWI3MWQ5MzQxOTkvdGFibGVyYW5nZTphZjdlMjM2ZDAzZTk0ZGE3OTAzY2VhYjcxZDkzNDE5OV8wLTEtMS0xLTA_8eab9267-8207-4924-b3d3-0f356cf049d1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6YWY3ZTIzNmQwM2U5NGRhNzkwM2NlYWI3MWQ5MzQxOTkvdGFibGVyYW5nZTphZjdlMjM2ZDAzZTk0ZGE3OTAzY2VhYjcxZDkzNDE5OV8xLTEtMS0xLTA_30a456bf-bf93-4822-a92b-d91e752f5160">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6YWY3ZTIzNmQwM2U5NGRhNzkwM2NlYWI3MWQ5MzQxOTkvdGFibGVyYW5nZTphZjdlMjM2ZDAzZTk0ZGE3OTAzY2VhYjcxZDkzNDE5OV8yLTEtMS0xLTA_c8378c1c-fadf-484a-bc98-c0b8bd05bb10">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6YWY3ZTIzNmQwM2U5NGRhNzkwM2NlYWI3MWQ5MzQxOTkvdGFibGVyYW5nZTphZjdlMjM2ZDAzZTk0ZGE3OTAzY2VhYjcxZDkzNDE5OV8zLTEtMS0xLTA_bd3646e5-0ded-4077-bff1-e103f95a3d92">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">on&#160;which&#160;registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6NTdhZTMzYjY4NGU3NDI4YzhmMGQzMzNkMDg4MTJjOGIvdGFibGVyYW5nZTo1N2FlMzNiNjg0ZTc0MjhjOGYwZDMzM2QwODgxMmM4Yl8xLTAtMS0xLTA_a41aa7b2-5aa1-486c-92e5-176b900e7cf3">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6NTdhZTMzYjY4NGU3NDI4YzhmMGQzMzNkMDg4MTJjOGIvdGFibGVyYW5nZTo1N2FlMzNiNjg0ZTc0MjhjOGYwZDMzM2QwODgxMmM4Yl8xLTItMS0xLTA_49b89cfd-2080-46b1-93cb-cd1b71764c4d">ALLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6NTdhZTMzYjY4NGU3NDI4YzhmMGQzMzNkMDg4MTJjOGIvdGFibGVyYW5nZTo1N2FlMzNiNjg0ZTc0MjhjOGYwZDMzM2QwODgxMmM4Yl8xLTQtMS0xLTA_153be002-d8d1-42ce-bafa-98726530f9e4">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b&#8211;2 of this chapter).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8xMTY0_b7ce4787-b427-48c9-af86-1540af7fdf46">&#9744;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id19c3483176340bcbb69140b53a9dc2e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2021 in the press release attached hereto as Exhibit&#160;99.1 and incorporated herein by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item&#160;2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="id19c3483176340bcbb69140b53a9dc2e_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20220223xexx9912021pr.htm">Press Release of the Company, dated February 23, 2022.</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id19c3483176340bcbb69140b53a9dc2e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALLOGENE THERAPEUTICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Chang, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: February 23, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>allo-20220223xexx9912021pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie3e255d4e38149ab96c4bf1fd4d9ec28_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt"><img alt="g725933allogenea06.jpg" src="g725933allogenea06.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:176px"></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Results and Provides Business Update</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">AlloCAR T&#8482; Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 1 Data from the ALPHA Trials in Relapsed&#47;Refractory (RR) Non-Hodgkin Lymphoma Presented at ASH 2021 Demonstrated Potential for an AlloCAR T Product to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Na&#239;ve Patients</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R&#47;R Large B Cell Lymphoma on Track to Commence Mid-Year 2022 Pending Ongoing FDA Discussions </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Phase 1 Data Presented at ASH 2021 from the ALLO-715 UNIVERSAL Trial in R&#47;R Multiple Myeloma Demonstrated Potential for an Allogeneic Anti-BCMA CAR T to Achieve Responses Similar to Approved Autologous CAR T Therapy with Added Benefit of Treatment within Five Days of Enrollment and Elimination of Bridging Therapy</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Ended 2021 with $810 Million in Cash, Cash Equivalents and Investments</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Conference Call and Webcast Scheduled for Today at 2&#58;00 PM PT&#47;5&#58;00 PM ET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SOUTH SAN FRANCISCO, Calif.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, February </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23, 2022</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene Therapeutics, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (Nasdaq&#58; ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T&#8482;) products for cancer, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;The FDA hold placed upon our clinical programs presented us with an unexpected challenge during the fourth quarter. In responding to and resolving this challenge, our team continued to demonstrate the qualities of leadership, collaboration, innovation, and focus that are required to be a pioneer in the field of allogeneic T cell therapy. I am incredibly proud of our employees&#8217; commitment and relentless belief in the potential for our products to improve the lives of patients,&#8221; said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. &#8220;Our mission has been, and continues to be, the first to bring allogeneic CAR T products to the market in blood cancers and solid tumors. We believe we are on track and have what it takes to execute on this vision and look forward to advancing our broad portfolio of product candidates.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Corporate Highlights</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 10, 2022, Allogene announced that the U.S. Food and Drug Administration (FDA) had removed the clinical hold on all AlloCAR T clinical trials which was announced on October 7, 2021. After extensive investigation by Allogene, it was determined that the chromosomal abnormality detected in a single patient treated with ALLO-501A was unrelated to TALEN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> gene editing or Allogene&#8217;s manufacturing process and had no clinical significance. The abnormality was not detected in any manufactured AlloCAR T product or in any other patient treated with the same ALLO-501A lot. The abnormality occurred after the cell product was administered and involved regions of the T cell receptor and immunoglobulin genes known to undergo rearrangement as part of the T cell or B cell maturation process.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene has resumed clinical study activities on ALLO-715 and ALLO-605 for relapsed&#47;refractory (R&#47;R) multiple myeloma (MM), and ALLO-316 for advanced or metastatic clear cell renal cell carcinoma (RCC), and began enrolling patients earlier this month. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Enrollment in the Phase 1 ALLO-501 ALPHA trial in R&#47;R non-Hodgkin lymphoma (NHL) has completed accrual. The focus remains on preparing for the pivotal Phase 2 ALPHA2 trial of ALLO-501A in R&#47;R Large B Cell Lymphoma (LBCL). Prior to the start of Phase 2, Allogene plans to resume enrollment in the Phase 1 study in order to offer AlloCAR T to patients in need.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Cell Forge 1 (CF1)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CF1, Allogene&#8217;s state-of-the-art manufacturing facility located in Newark, California is now fully operational and producing GMP material with the intent of supplying ALLO-501A for the planned pivotal study.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pipeline Updates</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-CD19 Program</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1 data from the ALPHA trial with ALLO-501 and ALPHA2 trial with ALLO-501A for the treatment of R&#47;R NHL was presented at the 2021 Annual American Society of Hematology (ASH) Annual Meeting. Data from these trials continue to support the promise of Allogene&#8217;s platform to provide a safe and durable alternative to approved autologous CAR T therapies in CAR T na&#239;ve patients. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Highlights from the ASH 2021 presentation include&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">AlloCAR T was associated with consistent and manageable safety with no dose limiting toxicities (DLTs) or graft-vs-host disease (GvHD) and minimal Grade 3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, or Grade 3 cytokine release syndrome (CRS). </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">There were no relapses observed in LBCL CAR T na&#239;ve patients across trials who had achieved a complete response (CR) at six months with the longest ongoing CRs with ALLO-501 at 18+ months and ALLO-501A at 15+ months.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">One of the most critical advantages of AlloCAR T was further established with more than 97% of enrolled patients able to receive therapy with the median time from enrollment to initiation of treatment of five days in ALPHA and two days in ALPHA2. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Phase 2 Preparation&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The single-arm ALPHA2 trial is on track to begin mid-year 2022 with FDA discussions directed at finalizing clinical trial design and proactively accelerating activities that address Chemistry Manufacturing and Controls (CMC) requirements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene is developing ALLO-647, its proprietary anti-CD52 monoclonal antibody intended to enable expansion and persistence of AlloCAR T product candidates, including ALLO-501A. Allogene intends to launch a separate registrational trial for ALLO-647 at the time of the pivotal Phase 2 trial for ALLO-501A as part of the concurrent development plan. This trial is intended to demonstrate the safety of ALLO-647 along with its contribution to the overall benefit of the lymphodepletion regimen. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Anti-BCMA AlloCAR T Program</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene&#8217;s anti-BCMA strategy includes the Phase 1 UNIVERSAL trial, which has cohorts evaluating ALLO-715 as a monotherapy, consolidated dosing of ALLO-715 using ALLO-647 to selectively extend the window of lymphodepletion, and ALLO-715 in combination with SpringWorks Therapeutics&#8217; investigational gamma secretase inhibitor, nirogacestat. The Phase 1 IGNITE trial is evaluating ALLO-605, Allogene&#8217;s first TurboCAR&#8482; candidate. TurboCAR technology allows cytokine activation signaling to be engineered selectively into CAR T cells and has shown the ability to improve the potency and persistence of allogeneic cells in preclinical models. Activity in these trials has resumed and Allogene intends to provide a BCMA program clinical update by the end of 2022. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">ALLO-715 UNIVERSAL Trial </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Data from the UNIVERSAL trial with ALLO-715 as a monotherapy for the treatment of R&#47;R MM was also presented at ASH 2021. The UNIVERSAL trial is the first allogeneic anti-BCMA CAR T to demonstrate safety and substantial efficacy in MM with response rates that are similar to the approved autologous CAR T therapy.  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The data presented at ASH demonstrated that ALLO-715 was well tolerated with no GvHD and a manageable safety profile. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">There was a 71% Overall Response Rate (ORR) at dose level 3 (320 million AlloCAR T+ cells) with lymphodepletion consisting of fludarabine&#47;cyclophosphamide and ALLO-647 </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">46% of patients achieved a Very Good Partial Response or better (VGPR+) including 25% Complete Response or Stringent Complete Response (CR&#47;sCR).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">92% of patients with VGPR+ were minimal residual disease (MRD) negative.  </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Median duration of response (DoR) was 8.3 months at the time of data cut-off.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Importantly, the study highlighted the ability to initiate treatment within five days of enrollment and eliminate the need for bridging therapy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Solid Tumor AlloCAR T Program</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">ALLO-316 (anti-CD70) &#8211; TRAVERSE Trial</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The Phase 1 trial for Allogene&#8217;s first AlloCAR T candidate for solid tumors, ALLO-316, is designed to evaluate the safety, tolerability, anti-tumor efficacy, pharmacokinetics, and pharmacodynamics of ALLO-316 in patients with advanced or metastatic clear cell RCC. Clinical trial activities have resumed. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fourth Quarter and Year-End Financial Results</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Research and development expenses were $54.0 million for the fourth quarter of 2021, which includes $11.1 million of non-cash stock-based compensation expense. For the full year of 2021, research and development expenses were $220.2 million. Research and development expense for the year includes $39.6 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General and administrative expenses were $20.0 million for the fourth quarter of 2021, which includes $10.9 million of non-cash stock-based compensation expense. For the full year of 2021, general and administrative expenses were $74.1 million, which includes $41.2 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Net loss for the fourth quarter of 2021 was $74.9 million, or $0.54 per share, including non-cash stock-based compensation expense of $22.0 million. For the full year of 2021, net loss was $257.0 million, or $1.89 per share, including non-cash stock-based compensation expense of $80.8 million.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The Company had $810 million in cash, cash equivalents, and investments as of December 31, 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Financial Guidance</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Allogene expects full year GAAP Operating Expenses to be between $360 million and $390 million including estimated non-cash stock-based compensation expense of $90 million to $100 million and excluding any impact from potential business development activities. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Conference Call and Webcast Details</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene will host a live conference call and webcast today at 2&#58;00 p.m. Pacific Time &#47; 5&#58;00 p.m. Eastern Time to discuss financial results and provide a business update. To access the live conference call by telephone, please dial 1 (866) 940-5062 (U.S.) or 1 (409) 216-0618 (International). The conference ID number for the live call is </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4973864</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The webcast will be made available on the Company's website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">About Allogene Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T&#8482;) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of &#8220;off-the-shelf&#8221; CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and follow &#64;AllogeneTx on Twitter and LinkedIn.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cautionary Note on Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as &#34;predicts,&#34; &#34;believes,&#34; &#34;potential,&#34; &#34;proposed,&#34; &#34;continue,&#34; &#34;estimates,&#34; &#34;anticipates,&#34; &#34;expects,&#34; &#34;plans,&#34; &#34;intends,&#34; &#34;may,&#34; &#34;could,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should&#34; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things&#58; the timing and ability to progress the ALPHA, ALPHA2, UNIVERSAL, IGNITE and TRAVERSE trials, including advancing to the Phase 2 portion of the ALPHA2 trial&#59; the timing and ability to initiate a registration trial for ALLO-647&#59; clinical outcomes, which may materially change as more patient data become available&#59; the ability to manufacture AlloCAR T&#8482; products, including obtaining FDA agreement to use ALLO-501A manufactured at the Company&#8217;s manufacturing facility for use in the ALPHA2 trial&#59; the potential benefits of AlloCAR T products&#59; and 2022 financial guidance. Various factors may cause differences between Allogene&#8217;s expectations and actual results as discussed in greater detail in Allogene&#8217;s filings with the SEC, including without limitation in its Form 10-K for the year ended December 31, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Statements comparing autologous CAR T data with AlloCAR T data should be viewed with caution, as they involve interpreting results from separate trials involving separate product candidates. There are differences in the clinical trial design, patient populations, published data, follow-up times and the product candidates themselves, and the results from the clinical trials of the autologous CAR T products may have no interpretative value on our existing or future results.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AlloCAR T&#8482; and TurboCAR&#8482; are trademarks of Allogene Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TALEN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is a registered trademark of Cellectis, S.A.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene&#8217;s AlloCAR T&#8482; programs utilize Cellectis technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. The anti-BCMA and anti-CD70 AlloCAR T programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these AlloCAR T programs.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie3e255d4e38149ab96c4bf1fd4d9ec28_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited&#59; in thousands, except share and per share data)</font></div><div id="ie3e255d4e38149ab96c4bf1fd4d9ec28_7"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,489&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,983&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,176&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,987&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,961&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,134&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,105&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,256&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,944&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,362&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,281&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,243&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,893)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,362)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,792)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,243)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,164&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,161)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(766)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,927)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,142)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(975)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,213)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,022&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,868)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,570)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257,005)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,221)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.54)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.53)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.89)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.08)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in computing net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,173,761&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,835,293&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,820,386&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,370,177&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="ie3e255d4e38149ab96c4bf1fd4d9ec28_10"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED BALANCE SHEET DATA</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and investments</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,481&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032,118&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,634&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227,829&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,212&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079,617&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allogene Media&#47;Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christine Cassiano</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Communications Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(714) 552-0326</font></div><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Christine.Cassiano&#64;allogene.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>allo-20220223.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2cb99d07-dd52-4e65-8d05-0da2093a6454,g:2b8cea13-1c6b-4c4b-bacc-6d5e7e0851da-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20220223" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20220223">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20220223_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20220223_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://allogene.com/role/DocumentandEntityInformationDocument">
        <link:definition>0001001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>allo-20220223_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2cb99d07-dd52-4e65-8d05-0da2093a6454,g:2b8cea13-1c6b-4c4b-bacc-6d5e7e0851da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_b537aa2a-0407-415b-aa32-b6c39923d903_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8379ed7b-9963-48c4-8794-0cc5eff6f1fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_af690ab1-8d3c-4733-b477-ad5cf8a3e6f5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_ae4be980-6b01-43f8-bb7a-0ac4c29dfe6d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f107f188-d5b0-4d21-abe2-cd6d708e93cc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_118b8758-a8d8-4e7e-9128-3dce394d86f8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b53b48e9-f65b-48ec-9642-f0226663650e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_11095890-c2d7-4f0d-9fad-710ffa076152_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_04cff7b5-25d2-4aea-89d5-ce1f89ca7737_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_2a3fcfe5-b3cd-430e-a5a0-7a820c112e32_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dbd2580f-0480-480a-9384-0e436eec6840_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e9310b90-845e-4712-98bc-d254ce92f89e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_de213af1-ad1d-42e3-92e3-c6766fbfb48b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e8d18d1b-4fbe-4c6d-9df3-7dc2913c955b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_23ff9ac8-9cb8-47d4-afa6-9ece25947d6d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d6fb50aa-2a33-4731-996d-7b97f54dc5c5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_760586ff-c790-4c1b-9e8d-9d909aed5dc6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4dc708db-b556-4b57-ac15-61063f6edc32_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_92788a2a-8d64-4faa-8a3b-e36b01f07b8c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_801dd892-78f8-4cd5-a111-d3ece2d9df2c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3dac29b5-de59-468c-b7ac-c7f908ece0fa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_a5866619-1b1b-4254-9667-a9944d389370_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8807a5bd-8470-4812-b2e2-1398ef077dcf_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>allo-20220223_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2cb99d07-dd52-4e65-8d05-0da2093a6454,g:2b8cea13-1c6b-4c4b-bacc-6d5e7e0851da-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="allo-20220223.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_212184ce-537e-4eec-be46-849589b19ed9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_DocumentType_212184ce-537e-4eec-be46-849589b19ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3c2f3c5c-233b-4f1e-9240-0431f507632a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_DocumentPeriodEndDate_3c2f3c5c-233b-4f1e-9240-0431f507632a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_05e61f2d-edf7-4036-ae9d-e271c13f3a73" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityRegistrantName_05e61f2d-edf7-4036-ae9d-e271c13f3a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bcaeec96-df27-4a77-abcb-433984064960" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityCentralIndexKey_bcaeec96-df27-4a77-abcb-433984064960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_701d83cb-84a3-4320-b25b-65bfbe514f7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_AmendmentFlag_701d83cb-84a3-4320-b25b-65bfbe514f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ba38116d-4518-4a51-ad35-cbc85d5d833b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ba38116d-4518-4a51-ad35-cbc85d5d833b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3c3db04d-8979-4b47-94ce-d803921555b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityFileNumber_3c3db04d-8979-4b47-94ce-d803921555b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_488e806f-a622-4ff6-bd9d-7c8fc14692cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityTaxIdentificationNumber_488e806f-a622-4ff6-bd9d-7c8fc14692cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0244536c-58fd-432e-bda2-b4cc185334c9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityAddressAddressLine1_0244536c-58fd-432e-bda2-b4cc185334c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d0d62831-fcfa-46f4-9d17-b7a7c89f2bf9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityAddressCityOrTown_d0d62831-fcfa-46f4-9d17-b7a7c89f2bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b1846df1-3783-44ac-b43c-83481630fc69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityAddressStateOrProvince_b1846df1-3783-44ac-b43c-83481630fc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_91afd05f-ecf3-4378-99ed-646ef8b21436" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityAddressPostalZipCode_91afd05f-ecf3-4378-99ed-646ef8b21436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_36b91c6b-4b8b-479f-9bc9-157df6660afa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_CityAreaCode_36b91c6b-4b8b-479f-9bc9-157df6660afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_58267330-b626-4214-8b0f-306dec101484" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_LocalPhoneNumber_58267330-b626-4214-8b0f-306dec101484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_1d5065dc-4c40-4a98-b49f-c55661148050" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_WrittenCommunications_1d5065dc-4c40-4a98-b49f-c55661148050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_bf5ccff1-88bd-4b47-aa57-5ac6d219ce8a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_SolicitingMaterial_bf5ccff1-88bd-4b47-aa57-5ac6d219ce8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_42737930-c7c5-4785-8fad-d1b574a527b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_PreCommencementTenderOffer_42737930-c7c5-4785-8fad-d1b574a527b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3e96a25a-7aea-466d-a711-97a0d378bf1b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3e96a25a-7aea-466d-a711-97a0d378bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cffb4703-9133-4b63-ab7d-494615c063c4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_Security12bTitle_cffb4703-9133-4b63-ab7d-494615c063c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7ab8fe0b-96a0-464f-8b9f-f0c5378be36f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_TradingSymbol_7ab8fe0b-96a0-464f-8b9f-f0c5378be36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a556a5eb-e441-4a8f-880c-808f55956384" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_SecurityExchangeName_a556a5eb-e441-4a8f-880c-808f55956384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a057db76-412d-4641-81b2-3a072c1ef3ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7d988bec-8069-4fad-b263-de6f1e75bcab" xlink:to="loc_dei_EntityEmergingGrowthCompany_a057db76-412d-4641-81b2-3a072c1ef3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g725933allogenea06.jpg
<TEXT>
begin 644 g725933allogenea06.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P ,P# 2(  A$! Q$!_\0
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M[Z7_ .AWU0_\%+#_ ,;^OV>?^O;0O_3A?5)^WC,L/_!Q/\"6;[OD:2OXF2^
M_G6U/['_ %[9PXQ_O,1_V%4_RB4_^"H!US_@H7_P5E\"_LTMJEWH_@?P^(;W
M4!:N"TTKVYNKBX*GY3(D 6&(L&\LO(P!W$5]H>*O^"-O[./B;X3R>$5^&>BZ
M7;^08H=3L%,>K6[8P)1='=(S@\_O"RD]5()%?'G_  5N\#^,/V%/^"B'@O\
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MPA^%\]QI%E8QB=EG,.P/$HB#,K7$^6DD7#-'"B[AM3'M/A^5HO\ @YYO]O\
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@]/Q^XYL3_9<:3A@:/LVY75E9*-MG[SN[];*^NU[+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140425941862552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 23,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>allo-20220223_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="allo-20220223.xsd" xlink:type="simple"/>
    <context id="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV80L2ZyYWc6MjAzZjdmYjUxYTE2NGVjMGJmMzZhYzc3NDllZDlhMTgvdGFibGU6NDIyYjViZmQ2Yjc5NGE0MWFhODM4NDZhNjk4NjFkMzYvdGFibGVyYW5nZTo0MjJiNWJmZDZiNzk0YTQxYWE4Mzg0NmE2OTg2MWQzNl8xLTEtMS0xLTA_29e4d5cb-e2d5-4637-8eb9-ef3ca2824f70">0001737287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV80L2ZyYWc6MjAzZjdmYjUxYTE2NGVjMGJmMzZhYzc3NDllZDlhMTgvdGFibGU6NDIyYjViZmQ2Yjc5NGE0MWFhODM4NDZhNjk4NjFkMzYvdGFibGVyYW5nZTo0MjJiNWJmZDZiNzk0YTQxYWE4Mzg0NmE2OTg2MWQzNl8yLTEtMS0xLTA_519950c1-4425-40a7-b649-c8aadcdfb303">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8xMDY_4cd8f04e-59c0-4688-ba94-634a5826f1e8">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8yNjY_3cf7a794-f36d-4502-b580-830dbddf37ce">2022-02-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8yOTM_38a87e8d-d662-4775-b335-f3c4522aef5e">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6MDk1NTQwNDg5NTYzNDExNGEyMDc5NTYyOTY2NzA4NzUvdGFibGVyYW5nZTowOTU1NDA0ODk1NjM0MTE0YTIwNzk1NjI5NjY3MDg3NV8wLTAtMS0xLTA_f63b5e90-0c46-4882-9d24-141375a4f9b8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6MDk1NTQwNDg5NTYzNDExNGEyMDc5NTYyOTY2NzA4NzUvdGFibGVyYW5nZTowOTU1NDA0ODk1NjM0MTE0YTIwNzk1NjI5NjY3MDg3NV8wLTEtMS0xLTA_b386ce20-0cf6-415f-8898-19914dab199d">001-38693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6MDk1NTQwNDg5NTYzNDExNGEyMDc5NTYyOTY2NzA4NzUvdGFibGVyYW5nZTowOTU1NDA0ODk1NjM0MTE0YTIwNzk1NjI5NjY3MDg3NV8wLTItMS0xLTA_32b45fca-d0e1-429c-86fd-01608932d206">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8zODI_8e1692bc-e01a-4763-b1a3-47586499b1e1">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8zODY_a3abd840-c04d-46ab-bbcf-a33932fb6a8c">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8zOTA_3723d742-3194-4c89-b83a-943025d12305">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8zOTM_c4d6cbda-b5e5-46ad-b9c9-88e1c037e292">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV81MDk_edde7a9d-0a06-4b54-b9c4-bf985579368e">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV81MTM_7ff9b300-96d2-4479-bc2d-1786ed857c66">457-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6YWY3ZTIzNmQwM2U5NGRhNzkwM2NlYWI3MWQ5MzQxOTkvdGFibGVyYW5nZTphZjdlMjM2ZDAzZTk0ZGE3OTAzY2VhYjcxZDkzNDE5OV8wLTEtMS0xLTA_8eab9267-8207-4924-b3d3-0f356cf049d1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6YWY3ZTIzNmQwM2U5NGRhNzkwM2NlYWI3MWQ5MzQxOTkvdGFibGVyYW5nZTphZjdlMjM2ZDAzZTk0ZGE3OTAzY2VhYjcxZDkzNDE5OV8xLTEtMS0xLTA_30a456bf-bf93-4822-a92b-d91e752f5160">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6YWY3ZTIzNmQwM2U5NGRhNzkwM2NlYWI3MWQ5MzQxOTkvdGFibGVyYW5nZTphZjdlMjM2ZDAzZTk0ZGE3OTAzY2VhYjcxZDkzNDE5OV8yLTEtMS0xLTA_c8378c1c-fadf-484a-bc98-c0b8bd05bb10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6YWY3ZTIzNmQwM2U5NGRhNzkwM2NlYWI3MWQ5MzQxOTkvdGFibGVyYW5nZTphZjdlMjM2ZDAzZTk0ZGE3OTAzY2VhYjcxZDkzNDE5OV8zLTEtMS0xLTA_bd3646e5-0ded-4077-bff1-e103f95a3d92">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6NTdhZTMzYjY4NGU3NDI4YzhmMGQzMzNkMDg4MTJjOGIvdGFibGVyYW5nZTo1N2FlMzNiNjg0ZTc0MjhjOGYwZDMzM2QwODgxMmM4Yl8xLTAtMS0xLTA_a41aa7b2-5aa1-486c-92e5-176b900e7cf3">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6NTdhZTMzYjY4NGU3NDI4YzhmMGQzMzNkMDg4MTJjOGIvdGFibGVyYW5nZTo1N2FlMzNiNjg0ZTc0MjhjOGYwZDMzM2QwODgxMmM4Yl8xLTItMS0xLTA_49b89cfd-2080-46b1-93cb-cd1b71764c4d">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGFibGU6NTdhZTMzYjY4NGU3NDI4YzhmMGQzMzNkMDg4MTJjOGIvdGFibGVyYW5nZTo1N2FlMzNiNjg0ZTc0MjhjOGYwZDMzM2QwODgxMmM4Yl8xLTQtMS0xLTA_153be002-d8d1-42ce-bafa-98726530f9e4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmQxOWMzNDgzMTc2MzQwYmNiYjY5MTQwYjUzYTlkYzJlL3NlYzpkMTljMzQ4MzE3NjM0MGJjYmI2OTE0MGI1M2E5ZGMyZV8xL2ZyYWc6YmUzNDFiZjZmZmM1NDlmZjgxMjRiNDhkZDRhZTJmYmEvdGV4dHJlZ2lvbjpiZTM0MWJmNmZmYzU0OWZmODEyNGI0OGRkNGFlMmZiYV8xMTY0_b7ce4787-b427-48c9-af86-1540af7fdf46">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ "(%75.%RMF3N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ "(%75)E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  (@5=4<I-#CE8$  "%$   &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ "(%75)^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  (
M@5=4EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  (@5=4'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ "(%75"0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ "(%75&60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="allo-20220223.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="allo-20220223.htm">allo-20220223.htm</File>
    <File>allo-20220223.xsd</File>
    <File>allo-20220223_lab.xml</File>
    <File>allo-20220223_pre.xml</File>
    <File>allo-20220223xexx9912021pr.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "allo-20220223.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "allo-20220223.htm"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20220223_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20220223_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "allo-20220223.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20220223",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220223.htm",
      "contextRef": "ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information Document",
     "role": "http://allogene.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20220223.htm",
      "contextRef": "ifdcaebc8211f4b15bcb20d7418a8bc73_D20220223-20220223",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001737287-22-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-22-000012-xbrl.zip
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MQ2FG2R7@O7H67]S;K@PC9V%5GM?#^'6K>8OS2B"A)%->R X5G]]#I4CV2+I
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M)P16'R$) K:3*PE )$7IB%/AAF$HB%"0I0C6*T#QY.[%]ME7J?5Z>0< +*'
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MO9!"R6(13Q@E,%.#$0D1GW ZSH(+$68 #05:@Y1P+/0*- M&(&F,O[JXPG7
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M^*I-NYH7LRE\@$T<[OX_4$L#!!0    (  B!5U3_>J?C@P(  ,\'   1
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M=GY[E("0D5#YGN ^-[XSHKZ;P9>,H]2*3E7B_Z0^G+PPG+0D#*$8-"L#QRD
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M$)O/DY3KU>13G3\77RQ")^LOG=77][E8+-L)Q90^/9N/J'?&!*Q0"((B'J5
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M>F8MY.JX'CE$W"]C+FJX6\+/D,SGS-/$O/"(,@99%F:.#.40/\Y($EA)1NV
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MQJMBR=>@_,AK2EN91YE"C 0'!#X,"MW 9!433EY.D05B$60\ER!FDDOF LA
M "-W,D'Z]"(,L"#U4IV?C"P6"@"PZZ'*H,-V9LN.OIP>]7LY"=W<GT:EOL39
MJ_(Z^FDT0 0R]3\98REGMU@A$PRS/Z[CW#XA6:#6BX+##73&T "#!""9.(4(
MBQL+]"VUSHR!(A,FC5D\IA @A2.5F_E&V@PEV'BS90RRD)2B!A440<F$VP2
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M=6JQJ3S"A!%3QVB^H^N18(+MNR:8Y8ZX<T502TJ@U$A9EK\!J0D= *IE;6Q
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MCARSC81JHV75FY4M5%\75)UZTZI4'J"_;\&Z&6"M6([S< _HFJD#&^@Z,.I
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M/9V1?QZ7>X#IOY&[ZSA-J^7<?9+7-N3Q$&H,A#L0@4C$2]0/O[##9WM:R":
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M,#(R,#(R,RYX<V102P$"% ,4    "  (@5=4-9VBNFD*  #.7@  %0
M        @ $E%P  86QL;RTR,#(R,#(R,U]L86(N>&UL4$L! A0#%     @
M"(%75+K_%>JS!@  NS$  !4              ( !P2$  &%L;&\M,C R,C R
M,C-?<')E+GAM;%!+ 0(4 Q0    (  B!5U05&HG>!2$  *4& 0 >
M      "  :<H  !A;&QO+3(P,C(P,C(S>&5X>#DY,3(P,C%P<BYH=&U02P4&
2      4 !0!0 0  Z$D

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
